Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma
- PMID: 10463973
Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma
Abstract
Background: Endoscopic ultrasonography (EUS) provides highly accurate preoperative T and N classifications in patients with esophageal carcinoma. Although previous data have suggested that patients with tumors classified as T4 by EUS do not benefit from surgical resection, these data were acquired prior to the widespread use of preoperative chemoradiation. The current study investigated whether pretreatment EUS can predict a complete response to neoadjuvant therapy.
Methods: Patients with esophageal carcinoma (adenocarcinoma or squamous cell carcinoma) underwent EUS classification prior to therapy. Patients classified as T2, T3, or T4 and M0 were treated with 5-fluorouracil, cisplatin, and radiation under protocol. Patients with T1 lesions underwent resection without prior chemoradiation. Chemoradiation was followed in all cases by attempted surgical resection. The initial EUS classification was compared with the final pathologic results.
Results: Fifty-five patients (47 males and 8 females) with a mean age of 60.5 years (range, 31-78 years) were evaluated. There were 41 adenocarcinomas and 14 squamous cell carcinomas. Among the total population, a complete response was achieved in 3 of 5 patients (60%) with tumors classified as T2 by EUS, 14 of 42 patients (33%) with tumors classified as T3 by EUS, and 5 of 8 patients (63%) with tumors classified as T4 by EUS (P = 0.19). A complete response was achieved in 9 of 24 patients (38%) found to have N0 disease by EUS versus 13 of 30 patients (43%) determined to have N1 disease (P = 0.66). The results for patients with adenocarcinoma and squamous cell carcinoma were similar.
Conclusions: The results of the current study demonstrate that pretreatment EUS does not predict reliably which patients with esophageal carcinoma will achieve a complete pathologic response to preoperative neoadjuvant chemoradiation.
Copyright 1999 American Cancer Society.
Comment in
-
Pretreatment staging by endoscopic ultrasonography does not predict complete response to neoadjuvant chemoradiation in patients with esophageal carcinoma.Cancer. 2000 Mar 1;88(5):1184-6. Cancer. 2000. PMID: 10699910 No abstract available.
Similar articles
-
The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy.Cancer. 2004 Sep 1;101(5):940-7. doi: 10.1002/cncr.20429. Cancer. 2004. PMID: 15329901
-
Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.Ann Thorac Surg. 2012 Jun;93(6):1855-9; discussion 1860. doi: 10.1016/j.athoracsur.2011.12.095. Epub 2012 Apr 18. Ann Thorac Surg. 2012. PMID: 22516835
-
Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation.Gastrointest Endosc. 1998 Aug;48(2):158-63. doi: 10.1016/s0016-5107(98)70157-9. Gastrointest Endosc. 1998. PMID: 9717781
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. doi: 10.1016/j.athoracsur.2004.04.046. Ann Thorac Surg. 2004. PMID: 15464463 Review.
-
[Management of esophageal squamous cell carcinoma and adenocarcinoma: surgical, endoscopic, and radiotherapeutic options].Med Clin (Barc). 2012 Dec 1;139(13):588-92. doi: 10.1016/j.medcli.2012.05.024. Epub 2012 Jul 28. Med Clin (Barc). 2012. PMID: 22841469 Review. Spanish. No abstract available.
Cited by
-
Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.World J Gastroenterol. 2012 Dec 21;18(47):7026-32. doi: 10.3748/wjg.v18.i47.7026. World J Gastroenterol. 2012. PMID: 23323004 Free PMC article.
-
Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?J Gastrointest Surg. 2013 Aug;17(8):1375-81. doi: 10.1007/s11605-013-2269-3. J Gastrointest Surg. 2013. PMID: 23797888
-
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus.BMC Cancer. 2001;1:20. doi: 10.1186/1471-2407-1-20. Epub 2001 Nov 23. BMC Cancer. 2001. PMID: 11737874 Free PMC article. Clinical Trial.
-
Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer.Oncotarget. 2017 May 2;8(18):30477-30494. doi: 10.18632/oncotarget.12955. Oncotarget. 2017. PMID: 27802185 Free PMC article. Review.
-
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.Ann Surg. 2005 Nov;242(5):684-92. doi: 10.1097/01.sla.0000186170.38348.7b. Ann Surg. 2005. PMID: 16244542 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical